Zentalis Pharmaceuticals Llc Stock Price Prediction

ZNTL Stock  USD 3.48  0.02  0.57%   
The relative strength index (RSI) of Zentalis Pharmaceuticals' the stock price is about 62. This usually means that the stock is rather overbought by investors as of now. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Zentalis, making its price go up or down.

Oversold Vs Overbought

62

 
Oversold
 
Overbought
The successful prediction of Zentalis Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Zentalis Pharmaceuticals and does not consider all of the tangible or intangible factors available from Zentalis Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Zentalis Pharmaceuticals Llc, which may create opportunities for some arbitrage if properly timed.
Using Zentalis Pharmaceuticals hype-based prediction, you can estimate the value of Zentalis Pharmaceuticals Llc from the perspective of Zentalis Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Zentalis Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Zentalis because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Zentalis Pharmaceuticals after-hype prediction price

    
  USD 3.48  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Zentalis Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Zentalis Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.152.948.84
Details
Naive
Forecast
LowNextHigh
0.062.898.79
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.543.404.25
Details

Zentalis Pharmaceuticals After-Hype Price Prediction Density Analysis

As far as predicting the price of Zentalis Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Zentalis Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Zentalis Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Zentalis Pharmaceuticals Estimiated After-Hype Price Volatility

In the context of predicting Zentalis Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Zentalis Pharmaceuticals' historical news coverage. Zentalis Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.17 and 9.38, respectively. We have considered Zentalis Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
3.48
3.48
After-hype Price
9.38
Upside
Zentalis Pharmaceuticals is very risky at this time. Analysis and calculation of next after-hype price of Zentalis Pharmaceuticals is based on 3 months time horizon.

Zentalis Pharmaceuticals Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Zentalis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zentalis Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Zentalis Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.27 
5.90
 0.00  
 0.00  
0 Events / Month
2 Events / Month
Any time
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
3.48
3.48
0.00 
0.00  
Notes

Zentalis Pharmaceuticals Hype Timeline

Zentalis Pharmaceuticals is at this time traded for 3.48. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Zentalis is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is at this time at 0.27%. %. The volatility of related hype on Zentalis Pharmaceuticals is about 619500.0%, with the expected price after the next announcement by competition of 3.48. About 98.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.65. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zentalis Pharmaceuticals recorded a loss per share of 2.5. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be any time.
Check out Zentalis Pharmaceuticals Basic Forecasting Models to cross-verify your projections.

Zentalis Pharmaceuticals Related Hype Analysis

Having access to credible news sources related to Zentalis Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Zentalis Pharmaceuticals' future price movements. Getting to know how Zentalis Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Zentalis Pharmaceuticals may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
SANASana Biotechnology 0.00 0 per month 0.00 (0.32) 7.20 (8.07) 23.40 
OLMAOlema Pharmaceuticals 0.00 0 per month 0.00 (0.08) 6.17 (5.89) 19.19 
CGEMCullinan Oncology LLC 0.00 0 per month 0.00 (0.18) 5.88 (7.24) 17.85 
LIFEATyr Pharma 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
GRCLGracell Biotechnologies 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
THRXTheseus Pharmaceuticals 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
GLUEMonte Rosa Therapeutics 0.00 0 per month 3.77  0.07  7.42 (8.18) 102.66 
DSGNDesign Therapeutics 0.00 0 per month 5.21  0.08  9.43 (7.45) 35.31 
ERASErasca Inc 0.03 7 per month 3.67 (0.03) 7.34 (5.38) 17.38 
DAWNDay One Biopharmaceuticals 0.00 0 per month 2.73 (0.05) 3.84 (3.69) 11.44 
INZYInozyme Pharma 0.00 0 per month 0.00 (0.34) 5.07 (7.92) 16.62 
SNDXSyndax Pharmaceuticals 0.00 0 per month 0.00 (0.08) 4.02 (4.33) 34.00 
PTGXProtagonist Therapeutics 0.00 0 per month 2.29 (0.0007) 3.70 (3.74) 14.61 
RVMDRevolution Medicines 0.00 0 per month 2.01  0.17  4.81 (3.24) 10.95 
BPMCBlueprint Medicines Corp 0.00 0 per month 2.58 (0.03) 4.90 (3.62) 14.28 
KYMRKymera Therapeutics 0.00 0 per month 0.00 (0.05) 4.84 (4.74) 18.10 
ITOSIteos Therapeutics 0.00 0 per month 0.00 (0.26) 4.26 (4.52) 33.24 
ICVXIcosavax(0.11)1 per month 4.56  0.13  10.22 (6.79) 38.57 
MRTXMirati Ther 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
VECTVectivBio Holding AG 0.06 7 per month 0.88  0.19  5.61 (3.08) 39.30 
ANNXAnnexon 0.00 0 per month 0.00 (0.07) 6.98 (5.26) 23.00 

Zentalis Pharmaceuticals Additional Predictive Modules

Most predictive techniques to examine Zentalis price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Zentalis using various technical indicators. When you analyze Zentalis charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Zentalis Pharmaceuticals Predictive Indicators

The successful prediction of Zentalis Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Zentalis Pharmaceuticals Llc, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Zentalis Pharmaceuticals based on analysis of Zentalis Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Zentalis Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Zentalis Pharmaceuticals's related companies.

Story Coverage note for Zentalis Pharmaceuticals

The number of cover stories for Zentalis Pharmaceuticals depends on current market conditions and Zentalis Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Zentalis Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Zentalis Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Zentalis Pharmaceuticals Short Properties

Zentalis Pharmaceuticals' future price predictability will typically decrease when Zentalis Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Zentalis Pharmaceuticals Llc often depends not only on the future outlook of the potential Zentalis Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zentalis Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding65.4 M
Cash And Short Term Investments482.9 M
When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:
Check out Zentalis Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.